Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2012

View Archived Issues

Small peptide ALK-3 agonist demonstrates regenerative potential in kidney

New encapsulated stem cell therapy induces cell death in gliomas

Notch mRNA signature biomarker monitors effects of PS-1-selective GSI

New JAK modulators described

Bayer Schering Pharma develops new vasopressin receptor ligands

New potential anticancer drugs developed in China

Novel RAR-related orphan receptor modulators presented

Novel potential hepatitis therapies reported

Actelion divulges novel orexin receptor antagonists

Phase II BTA-798 trial meets primary endpoint

MorphoSys receives milestone payment from Novartis

Final phase III Heplisav data are encouraging

FDA approves line extension for etravirine

Search for novel triple reuptake inhibitors yields ALB-109780

Lorus Therapeutics presents preclinical data on small-molecule antimicrobial

NGM and Daiichi Sankyo to collaborate on novel diabetes therapies

BioSeek and Merck Serono extend BioMAP collaboration

Chelsea Therapeutics receives complete response letter regarding Northera

Allergan seeks approval for line extension of Botox

Protox advances PRX-302 trial

Treatment begins in first-in-human CO-1686 study

DSMB recommends continuation of Menerba study

Trillium Therapeutics doses first patient in phase I trial of TTI-1612

Ultragenyx obtains orphan drug designations in Europe for two lead products

Gruenenthal reports new potassium channel modulators

JDRF and iCo Therapeutics join to support iDEAL trial

Depomed receives remaining license fee payment in Acuform collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 18, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...